| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Acrivon Therapeutics, Inc. (ACRV) has 14 insiders with recent SEC Form 4 filings, including 1 buy and 0 sells. ACRV is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 2.10M | $4.03M | - | |
| Other | 225.0K | $433.1K | - | |
| COO | 75.3K | $145.0K | - | |
| Other | 33.1K | $63.8K | - | |
| CFO | 21.0K | $40.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 17, 2022 | Ra Capital Management, L.P.52 | Director, 10% Owner | Buy | 3,389,500 | $12.50 | $42,368,750.00 | +340.8% | +43.1% | -75.3% |